Alto Neuroscience Inc. (ANRO)
Alto Neuroscience Inc. (ANRO) Stock Price, Analysis & Data
| Cours acheteur | 18.4 |
| Capitalisation boursière | 1.26B |
| Chiffre d’affaires (ttm) | n/a |
| Résultat net (ttm) | -84.24M |
| Bêta | 1.09 |
| EPS (ttm) | -2.32 |
| Ratio P/E (ttm) | n/a |
| P/E prévisionnel | -9.57 |
| P/B (ttm) | 5.14 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 11, 2026 |
| Cours vendeur | n/a |
| Volume | 494,930 |
| Volume moy. (20D) | 517,500 |
| Ouverture | 31.77 |
| Clôture précédente | 32.30 |
| Fourchette du jour | 29.88 - 32.29 |
| Intervalle de 52 semaines | 3.05 - 33.67 |
| Analyste | Strong Buy |
| Objectif de prix | 37 (15.12%) |
| Dividendes | n/a |
| Date ex-dividende | n/a |
À propos de ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive d...
Performance financière
En 2025, le chiffre d’affaires de Alto Neuroscience s’élevait à 0, soit une hausse de undefined% par rapport aux 0 de l’année précédente. Le bénéfice s’élevait à -63.24M, soit une hausse de 2.94%.
États financiersPrévisions des analystes
Selon les évaluations de 9 analystes, la note moyenne de l’action ANRO est « Strong Buy ». L’objectif de cours moyen à 12 mois est de 37, soit une hausse de 15.12 % par rapport au dernier cours.
Prévisions boursièresSurprise sur les résultats
Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure
9 heures il y a · Simply Wall St.
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?Alto Neuroscience (ANRO) is back in focus after reporting second quarter 2026 results. The company reported a net loss of US$27.64 million and a basic loss per share from continuing operations of US$0...
21 heures il y a · Simply Wall St.
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?Alto Neuroscience, Inc. reported its second-quarter and first-half 2026 results, recording a wider net loss of US$27.64 million for Q2 and US$53.88 million for the six months ended June 30, 2026, with...
1 jour il y a · Simply Wall St.
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 PlansAlto Neuroscience stock has delivered a very large gain over the past year, yet the valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Over the last ...
